Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia

(2016) Charles L. Bennett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system

(2016) Dennis W. Raisch et al.   Expert Opinion On Drug Safety

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay

(2016) Denise Campagnolo et al.   JOURNAL OF NEUROVIROLOGY

Reassessing the risk of natalizumab-associated PML

(2016) Joseph R. Berger et al.   JOURNAL OF NEUROVIROLOGY

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy

(2016) Julian Borchardt et al.   Multiple Sclerosis and Related Disorders

Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database

(2015) Gorana Capkun et al.   Multiple Sclerosis and Related Disorders

Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients

(2014) Luiz Henrique da Silva Nali et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

(2014) Kenneth R. Carson et al.   CANCER

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

(2014) H. Butzkueven et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A systematic review of the incidence and prevalence of cancer in multiple sclerosis

(2014) Ruth Ann Marrie et al.   Multiple Sclerosis Journal

Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies

(2014) Ferrán Catalá-López et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Risk for Nevus Transformation and Melanoma Proliferation and Invasion During Natalizumab Treatment

(2014) Momen Pharaon et al.   JAMA Dermatology

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Natalizumab Therapy for Multiple Sclerosis

(2013) Jens Kuhle et al.   SEMINARS IN NEUROLOGY

Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR)

(2012) Thomas Moore et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Pharmacovigilance and PML in the oncology setting

(2011) C. L. BENNETT   CLEVELAND CLINIC JOURNAL OF MEDICINE

Natalizumab (Tysabri)

(2010) D.T. Selewski et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Diagnosis of melanoma under concomitant natalizumab therapy

(2010) Bettina M Prinz Vavricka et al.   Multiple Sclerosis Journal

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report

(2010) A. Laroni et al.   NEUROLOGICAL SCIENCES

Natalizumab et nævus atypiques : commentaires sur la note de pharmacovigilance de J.-L. Schmutz et al.

(2009) Ö. Yaldizli et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis

(2009) Azza Ismail et al.   JOURNAL OF NEUROLOGY

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

(2009) Roberto Bergamaschi et al.   Multiple Sclerosis Journal

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis

(2008) John T. Mullen et al.   NEW ENGLAND JOURNAL OF MEDICINE